India Gives Lundbeck Six Months To Prove Deaxit Safe Or Face A Ban
This article was originally published in PharmAsia News
Executive Summary
Under fire from a parliamentary committee, India's Drugs Controller General of India has given Lundbeck six months to show its Deaxit (flupenthixol/melitracen) is safe and effective or pull it from the market.